BioCryst Pharmaceuticals (BCRX) Competitors $7.22 -0.03 (-0.41%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$7.24 +0.02 (+0.28%) As of 10/10/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX vs. ALKS, LGND, FOLD, CLDX, MNKD, NVAX, OPK, DVAX, INVA, and ZBIOShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. BioCryst Pharmaceuticals vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind Novavax OPKO Health Dynavax Technologies Innoviva Zenas BioPharma BioCryst Pharmaceuticals (NASDAQ:BCRX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability. Which has better valuation and earnings, BCRX or ALKS? Alkermes has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$450.71M3.36-$88.88M-$0.18-40.11Alkermes$1.56B3.31$367.07M$2.0815.00 Is BCRX or ALKS more profitable? Alkermes has a net margin of 23.15% compared to BioCryst Pharmaceuticals' net margin of -6.41%. Alkermes' return on equity of 24.86% beat BioCryst Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-6.41% N/A -1.78% Alkermes 23.15%24.86%17.14% Do institutionals & insiders have more ownership in BCRX or ALKS? 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 5.1% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 4.4% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to BCRX or ALKS? In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Alkermes. MarketBeat recorded 7 mentions for BioCryst Pharmaceuticals and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.65 beat BioCryst Pharmaceuticals' score of 0.55 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, BCRX or ALKS? BioCryst Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Do analysts prefer BCRX or ALKS? BioCryst Pharmaceuticals presently has a consensus price target of $16.30, indicating a potential upside of 125.76%. Alkermes has a consensus price target of $42.00, indicating a potential upside of 34.57%. Given BioCryst Pharmaceuticals' higher probable upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.75Alkermes 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93 SummaryAlkermes beats BioCryst Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.52B$2.65B$6.10B$10.63BDividend YieldN/A56.72%5.67%4.71%P/E Ratio-40.1122.9185.2726.57Price / Sales3.36745.20612.78132.63Price / CashN/A179.8938.5062.09Price / Book-3.145.3712.726.53Net Income-$88.88M$32.78M$3.30B$275.96M7 Day Performance0.98%2.34%0.94%-0.73%1 Month Performance-10.53%8.04%6.34%3.71%1 Year Performance-2.83%-1.76%80.41%37.30% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals4.05 of 5 stars$7.22-0.4%$16.30+125.8%+1.4%$1.52B$450.71M-40.11530Analyst ForecastALKSAlkermes4.3491 of 5 stars$30.99-0.2%$42.00+35.5%+14.0%$5.12B$1.51B14.901,800LGNDLigand Pharmaceuticals3.8983 of 5 stars$182.61+0.9%$176.50-3.3%+77.2%$3.58B$187.58M-45.6580News CoverageAnalyst ForecastFOLDAmicus Therapeutics4.4891 of 5 stars$8.16-0.5%$15.78+93.4%-17.4%$2.52B$571.16M-67.99480Analyst ForecastAnalyst RevisionCLDXCelldex Therapeutics2.2314 of 5 stars$26.38-0.1%$46.13+74.8%-9.8%$1.75B$7.02M-8.76150Analyst ForecastMNKDMannKind4.0102 of 5 stars$5.66-1.7%$11.17+97.3%-22.8%$1.74B$285.50M51.46400News CoverageAnalyst ForecastNVAXNovavax4.232 of 5 stars$9.08-4.0%$14.29+57.3%-35.5%$1.47B$1.08B3.981,990Analyst ForecastOPKOPKO Health4.2813 of 5 stars$1.58+1.3%$2.63+66.1%+2.7%$1.24B$664.03M-6.322,997Analyst ForecastDVAXDynavax Technologies4.474 of 5 stars$10.14+0.4%$24.33+140.0%-3.1%$1.19B$316.27M-22.04350Analyst ForecastINVAInnoviva4.7656 of 5 stars$17.42-0.3%$37.60+115.8%-11.0%$1.10B$358.71M56.20100Analyst ForecastZBIOZenas BioPharma2.44 of 5 stars$23.03+5.8%$36.67+59.2%N/A$969.79M$5M-6.49N/ATrending NewsAnalyst ForecastInsider TradeGap Up Related Companies and Tools Related Companies ALKS Competitors LGND Competitors FOLD Competitors CLDX Competitors MNKD Competitors NVAX Competitors OPK Competitors DVAX Competitors INVA Competitors ZBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCRX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
